• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Affimed N.V.

    11/14/24 7:01:56 AM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    6-K 1 d913155d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

    For the month of November, 2024

    Commission File Number: 001-36619

     

     

    Affimed N.V.

     

     

    Gottlieb-Daimler-Straße 2,

    68165 Mannheim

    Germany

    (Address of principal executive offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

    ☒ Form 20-F   ☐ Form 40-F

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     


    INCORPORATION BY REFERENCE

    Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-282978), Form S-8 (Registration Number 333-198812) and Form S-8 (Registration Number 333-270798) of Affimed N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    Exhibit 99.3 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        AFFIMED N.V.
    Date: November 14, 2024     By:  

    /s/ Shawn Leland

        Name:   Shawn Leland
        Title:   Chief Executive Officer
        By:  

    /s/ Denise Mueller

        Name:   Denise Mueller
        Title:   Chief Business Officer


    EXHIBIT INDEX

     

    Exhibit    Description of Exhibit
    99.1    Affimed N.V. Unaudited Condensed Consolidated Interim Financial Statements as of September 30, 2024.
    99.2    Affimed N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
    99.3    Affimed N.V. Press Release dated November 14, 2024.
    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Outperform → Market Perform
    Leerink Partners
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    More analyst ratings

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Announces Receipt of Nasdaq Delisting Notice

      MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq")

      5/14/25 6:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Filing for the Opening of Insolvency Proceedings

      MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the "Company") has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and

      5/13/25 8:15:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Affimed Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Affimed Therapeutics from Buy to Neutral

      5/14/25 8:54:15 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Therapeutics downgraded by Leerink Partners

      Leerink Partners downgraded Affimed Therapeutics from Outperform to Market Perform

      5/13/25 8:52:30 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Affimed Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00

      12/12/22 7:32:36 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care